Accreditation/Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint provider-ship of the University of Cincinnati and Physicians' Education Resource®, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation:

The University of Cincinnati designates this enduring material activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca; Janssen Scientific Affairs, LLC and Pharmacyclics LLC, an AbbVie Company.

Medical Crossfire®: What Informs Our Clinical Decisions in CLL Management? Key Evidence to Stratify Risk and Optimize Sequencing

Release Date: October 31, 2019
Expiration Date: October 31, 2020
Media: Enduring Material - Internet - based

Activity Overview

In this online educational program, chaired by William G. Wierda, MD, PhD, top faculty in the field of chronic lymphocytic leukemia (CLL) and including Ian W. Flinn, MD, PhD; Anthony Mato, MD, MSCE; and Paolo Strati, MD, discuss current and emerging evidence-based therapeutics applicable to patients with CLL. The panel members explain risk stratification, therapeutic monitoring, sequencing, and combination strategies for the treatment of CLL in the frontline setting, as well as for relapsed/refractory disease. Discussion also focuses on the role of molecular and cytogenetic testing in CLL at this prolific moment of emerging mechanisms, compounds, and approaches. The faculty offer clinical perspectives and contrasting viewpoints on the application of clinical trial results and distinguish among the new small molecules currently being investigated in CLL. Through a comprehensive discussion of the evolving strategies for management of patients with CLL, participants will encounter practice-changing perspectives with the potential to improve patient outcomes in clinical practice.

Benefits of Participating

  • Review the latest clinical trial evidence in context using clinical cases to optimize decision making in CLL
  • Hear contrasting views on treatment strategies and discover areas for further research in CLL
  • Learn the thought process of experts behind the management of specific patient cases across CLL and use these perspectives to confirm and update your practice
  • Apply the latest data to select treatments with the goal to minimize adverse events and reduce toxicity in patients with CLL

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca; Janssen Scientific Affairs, LLC and Pharmacyclics LLC, an AbbVie Company.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a continuing medical education (CME) certificate, you must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This activity is intended for medical oncologists, hematologists, and other oncology healthcare professionals interested in the latest advances in the treatment of patients with CLL.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Explain evidence-based therapeutic sequencing considerations and combination strategies for the treatment of CLL in the context of emerging strategies under clinical trial evaluation
  • Distinguish among new small molecules under investigation for patients with CLL based upon mechanism of action, as well as recent safety and efficacy data
  • Apply biomarker testing results to stratify risk among patients with CLL in frontline and relapsed/refractory treatment settings
  • Use methods to optimize therapeutic efficacy and safety among patients with CLL in the context of emerging compounds and combination strategies

Faculty, Staff, and Planners’ Disclosures

Faculty

William G. Wierda
William G. Wierda, MD, PhD
D.B. Lane Cancer Research Distinguished Professor, Department of Leukemia, Division of Cancer Medicine
Head of Chronic Lymphocytic Leukemia Section, Department of Leukemia
Medical Director, Leukemia Center
Executive Medical Director, Hematologic Malignancies
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: AbbVie, Acerta Pharma, Genentech, Gilead, Juno Therapeutics, Karyopharm, Kite Pharma, miRagen, Pharmacyclics, Novartis Slovakia, Sunesis; Consultant: Sanofi.

Anthony Mato
Anthony Mato, MD, MSCE
Director, Chronic Lymphocytic Leukemia Program
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant Research Support: Johnson & Johnson, Loxo Oncology, Pharmacyclics, Regeneron, Sunesis, TG Therapeutics; Consultant: Celgene, Johnson & Johnson, Loxo Oncology, Pharmacyclics, Regeneron, Sunesis, TG Therapeutics.

Ian W. Flinn
Ian W. Flinn, MD, PhD
Director, Lymphoma Research Program
Sarah Cannon Research Institute
Nashville, TN

Disclosures: Grant Research Support: AbbVie, Acerta Pharma, Agios, BeiGene, Calithera, Celgene, Constellation Pharmaceuticals, Curtis, Forma Therapeutics, Forty-Seven, Genentech, Gilead, Incyte, Infinity Pharmaceuticals, Janssen, Karyopharm, Kite Pharma, Merck, Novartis, Pfizer, Pharmacyclics, Portola, Roche, Seattle Genetics, Teva Pharmaceutical Industries Ltd, TG Therapeutics; Consultant: AbbVie, Takeda, TG Therapeutics, Trillium Therapeutics Inc, Verastem Oncology.

Paolo Strati
Paolo Strati, MD
Assistant Professor, Department of Lymphoma and Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Disclosures: no relevant financial relationships with commercial interest to disclose.

The staff of University of Cincinnati and Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of the University of Cincinnati and PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, the University of Cincinnati and PER® require everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, the University of Cincinnati and PER® are required by ACCME to resolve all COI. The University of Cincinnati and PER® have identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of the University of Cincinnati or PER® or the company that provided commercial support.

CME Provider Contact Information

The University of Cincinnati
Continuing Medical Education
PO Box 670556
Cincinnati, Ohio 45267-0556
(513) 558-7277
uc-cloudcme@ucmail.uc.edu


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
  12345
6789101112
13141516171819
20212223242526
27282930
Filter By